It was MHRA-approved on 11 June 2026 for adults with obesity, or those overweight with a weight-related condition
For compounding pharmacies or physicians that have been compounding semaglutide products during the shortage, the FDA has set clear deadlines for ceasing general semaglutide compounding practices: State-licensed pharmacies or physicians compounding semaglutide under Section 503A of the FD&C Act must stop compounding, distributing, or dispensing semaglutide injections that are essentially copies of an FDA-approved product by April 22, 2025
A randomized clinical trial published in JAMA Psychiatry in 2025 reported reduced alcohol cravings and fewer heavy drinking days among people taking semaglutide compared to placebo, consistent with patterns noted in other emerging observational research and clinical reports
Key Features: Comprehensive Cardiovascular Support Contains Omega-3 fatty acids EPA and DHA, which contribute to normal heart function and help regulate cholesterol levels
Thats why we also support patients from Hollis to Bow and Derry with strategies for hormone balance, digestion, stress reduction, and sleep